Nrx Pharma To Begin Phase 3 Trial Of Nrx-101 To Treat Bipolar Depression With Acute Suicidality
Nrx Pharmaceuticals, Inc., A Clinical-Stage Biopharmaceutical Company, Announced That Its First Clinical Trial Site Has Been Contracted (With Others Expected In Near Future) And That First Dosing Of Patients Is Expected In Early 2023.This Phase 3 Clinical Trial Of Nrx-101 Is For The Treatment Of Severe Bipolar Depression With Acute Suicidal Ideation And Behaviour (Sbd-Asib), A Lethal Condition That Currently Takes The Lives Of Thousands Of Americans Each Year. Nrx-101 Is The First Investigational Medicine To Target This Condition, For Which The Only Currently Approved Treatment Is Electroconvulsive Therapy.Based On Preliminary Efficacy Demonstrated In The Company
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
